[Therapy of carcinoma of the oral cavity and the mesopharynx].
From the period 1969-1984 the progresses of 93 patients could be analysed, which were treated because of a squamous cell carcinoma of the mouth-cavity and the mesopharynx. Different therapeutic modalities and the prognostic relevance of locoregional tumor starting situation were analysed at criterion of survival. 44.8% of tumors of category T1, 23.3% of T2, 22.2% of T3 and 0% of T4 lived 5 years later. Only 18 months later T4-tumors turned prognostically worse. Only in fixed lymph-node of the neck (N3-category) the prognosis grew worse in our patients. The global 5-years-survival was 25.8% only. Sole operation and combination of short-time preirradiation, operation and postoperative dose-saturation gave the same 5-years-survivals (40% or 43%), in prognostically more auspicious patients in starting situation for the sole operation. From the groups of combined radiologically-surgically treated patients these ones were observed separately, whose tumors could not be removed within the healthy tissue. In these patients a pre- and postoperatively irradiation shows a little better results than postoperative radiotherapy alone, both concerning the mean survival and the 5-years-survival too. For carcinomas of the mouth-cavity (T1N0) the sole operation is the adequate treatment. For all the other cases the medium-high short-time preirradiation with operation and, depending on findings, postoperative dose-saturation should be considered. Plastic reconstructive measures can be planned 24 months later, because after this period the survival rates stay constant.
D
D
Hamann
M
M
Sonnenburg
U
U
Oll
D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000628:therapy*; D009959:Oropharyngeal Neoplasms / Q000628:therapy*; D010610:Pharyngeal Neoplasms / Q000628:therapy*; D011379:Prognosis
Ein Beitrag zur Therapie des Mundhöhlen- und Mesopharynxkarzinoms.